dc.contributor.author | Eskazan, Ahmet Emre | |
dc.date.accessioned | 2021-03-03T17:59:31Z | |
dc.date.available | 2021-03-03T17:59:31Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Eskazan A. E. , "Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, cilt.84, sa.8, ss.1635-1638, 2018 | |
dc.identifier.issn | 0306-5251 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_4c9d5602-b5d8-48b9-8c15-8f1f7cac329d | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/54850 | |
dc.identifier.uri | https://doi.org/10.1111/bcp.13637 | |
dc.language.iso | eng | |
dc.subject | Temel Bilimler | |
dc.subject | Eczacılık | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.title | Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes? | |
dc.type | Makale | |
dc.relation.journal | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | |
dc.contributor.department | İstanbul Üniversitesi , Açık ve Uzaktan Eğitim Fakültesi , Coğrafya | |
dc.identifier.volume | 84 | |
dc.identifier.issue | 8 | |
dc.identifier.startpage | 1635 | |
dc.identifier.endpage | 1638 | |
dc.contributor.firstauthorID | 255070 | |